An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.

Trial Profile

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Feb 2018 A first interim analysis for safety is planned after 18 patients enrolled and treated (by December 1st, 2017).
    • 10 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium
    • 28 Mar 2017 Trial designed were presented at the 32nd Congress of the European Association of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top